C57BL/6-Tg(TRAMP)8247Ng/J

Stock number: 003135
Product name: B6 TRAMP mice
Research areas: Cancer Research, Reproductive Biology Research

Description

These mice harbor the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP); PB-Tag Line 8247 transgene. Mice hemizygous for the TRAMP transgene develop progressive forms of prostate cancer with distant site metastasis and exhibit various forms of disease from mild intraepithelial hyperplasia to large multinodular malignant neoplasia.

In 2019, sequencing performed by The Jackson Laboratory discovered that greater than 20 copies of the Tg(TRAMP)8247Ng transgene (hemizygous) integrated on chromosome 16 (~18,993,000-19,272,880; mouse mm10). The region surrounding the integration site has duplicated. Currently, there are no genes annotated in this region.

Detailed description

These mice harbor the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP); PB-Tag Line 8247 transgene. Mice hemizygous for the TRAMP transgene develop progressive forms of prostate cancer with distant site metastasis and exhibit various forms of disease from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. TRAMP hemizygotes can exhibit prostatic epithelial neoplasia (PIN) by 12 weeks of age. Tumors, appearing as well differentiated adenocarcinoma, can arise by 24 weeks of age, mostly in the dorsal and lateral lobes of the prostate. By 30 weeks of age, most hemizygous mice will display evidence of metastatic spread to the lymph nodes and/or lungs, phylloides appearance of some tumors, and seminal vesicle invasion. Tumors exhibit elevated levels of nuclear TRP53 and decreased androgen receptor expression. Note that pure C57BL/6 TRAMP hemizygotes may live to 52 weeks of age or longer.

The Jackson Laboratory Genetic Quality Control group data: Stock No. 003135 Cryorecovered and Repository Cohorts Exhibit Expected Spontaneous Tumors 2022-2023 [view data].

Development

These TRAMP transgenic mice were developed in the laboratory of Dr. Norman M. Greenberg at Baylor College of Medicine. The TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) transgenic construct was designed with simian virus 40 (SV40) early genes (large and small tumor antigens, Tag) under the control of the rat probasin promoter. The founder mouse (line 8247) described in the primary publication is one that developed a large prostate tumor by 10 weeks of age and was generated on a C57BL/6 background. The donating investigator maintains the strain by breeding hemizygous females with C57BL/6 males. The strain has been backcrossed to C57BL/6 for 20+ generations.

In 2019, sequencing performed by The Jackson Laboratory discovered that greater than 20 copies of the Tg(TRAMP)8247Ng transgene (hemizygous) integrated on chromosome 16 (~18,993,000-19,272,880; mouse mm10). The region surrounding the integration site has duplicated. Currently, there are no genes annotated in this region.

Allele

Symbol: Tg(TRAMP)8247Ng
Name: transgene insertion 8247, Norman M Greenberg
MGI accession ID: MGI:2384595
Generation method: Transgenic
Attributes: Inserted expressed sequence
Synonyms: PB-Tag; probasin/Tag; Tg(Pbsn-TAg)8247Ng; TRAMP
Marker symbol: Tg(TRAMP)8247Ng
Marker name: transgene insertion 8247, Norman M Greenberg
Marker synonyms: TRAMP
Chromosome: 16
Strain of origin: C57BL/6
Expressed genes: TAg,SV40 large T-antigen,SV40
Molecular note: Expression of the SV40 early region tumor antigen was driven in mouse prostate epithelium via a rat probasin promoter region fragment (-426/+28 bp). Sequencing identified greater than 20 copies of the Tg(TRAMP)8247Ng transgene (hemizygous) integrated on chromosome 16 (~18,993,000-19,272,880; mouse mm10). The region surrounding the integration site has duplicated. Currently, there are no genes annotated in this region.
General note: TRAMP stands for TRansgenic Adenocarcinoma Mouse Prostate. Lines 5666 and 8079 were also produced.

Transgenic mice on a C57BL6 background develop progressive forms of prostate cancer with distant site metastasis. Forms of disease range from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. Tumors are detected in the prostate as early as 10 weeks of age. The tumors have elevated levels of nuclear TRP53 and decreased androgen receptor expression.